Back to top
more

ShockWave Medical (SWAV)

(Delayed Data from NSDQ)

$334.01 USD

334.01
1,964,117

+4.37 (1.33%)

Updated May 22, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (144 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Factors That Make Centene (CNC) an Attractive Bet for Investors

by Zacks Equity Research

Centene (CNC) rides on continued top-line growth and numerous contract wins. Divestitures and an adequate cash-generating ability equip CNC well to invest in growth-related initiatives.

Merit Medical (MMSI) Launches New Soft Tissue Biopsy System

by Zacks Equity Research

Merit Medical's (MMSI) launch of the TEMNO Elite Soft Tissue Biopsy System will boost its portfolio of biopsy devices.

PacBio's (PACB) New Method for TR Profiling Now Available

by Zacks Equity Research

PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.

3 Reasons to Hold Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips

by Zacks Equity Research

The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.

Here's Why Investors Should Hold Exact Sciences (EXAS) Stock

by Zacks Equity Research

Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.

Stryker (SYK) Launches Q Guidance System for Spine Applications

by Zacks Equity Research

Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during guided spine surgery following its launch.

3 Reasons to Retain CONMED (CNMD) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Encompass Health (EHC) Plans Hospital to Aid Florida Footprint

by Zacks Equity Research

Encompass Health (EHC) unveils plans to fortify its U.S. presence via building a 50-bed inpatient rehabilitation hospital in The Villages, Florida.

PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows

by Zacks Equity Research

PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay

by Zacks Equity Research

Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain momentum from robust medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.

Is Motion Acquisition (DCGO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how DocGo Inc. (DCGO) and Shockwave Medical (SWAV) have performed compared to their sector so far this year.

Shockwave Medical (SWAV) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Shockwave Medical (SWAV) closed at $254.79, marking a +1.08% move from the previous day.

3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

ResMed (RMD) Gains on Product Uptake Even as Expenses Rise

by Zacks Equity Research

The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.

Here's Why You Should Hold on to OPKO Health (OPK) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod

by Zacks Equity Research

Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.

Bruker (BRKR) Gains From New Product Bookings Amid Competition

by Zacks Equity Research

Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.

    Walgreens Boots' (WBA) Product Expansion Aids Amid Rivalry

    by Zacks Equity Research

    Sales contributions from Walgreens Boots' (WBA) newly-formed Walgreens Health segment instill investors' optimism.

    Here's Why Investors Should Retain Amedisys (AMED) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.

    PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance

    by Zacks Equity Research

    PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.

    Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.